Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3

Åsa Alsiö; Karolina Rembeck; Galia Askarieh; Peer Brehm Christensen; Martti Färkkilä; Nina Langeland; Mads Rauning Buhl; Court Pedersen; Kristine Mørch; Bart L Haagmans; Salmir Nasic; Johan Westin; Kristoffer Hellstrand; Gunnar Norkrans; Martin Lagging

doi:10.1371/journal.pone.0037521

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3

Åsa Alsiö
, Karolina Rembeck
, Galia Askarieh
, Peer Brehm Christensen
, Martti Färkkilä
, Nina Langeland
, Mads Rauning Buhl
, Court Pedersen
, Kristine Mørch
, Bart L Haagmans
, Salmir Nasic
, Johan Westin
, Kristoffer Hellstrand
, Gunnar Norkrans
, Martin Lagging

KI, OUH, Forskningsenhed for Infektionsmedicin (Odense)

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.

Originalsprog	Engelsk
Tidsskrift	PLOS ONE
Vol/bind	7
Udgave nummer	5
Sider (fra-til)	e37521
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0037521
Status	Udgivet - 2012

Dokumenter og links

10.1371/journal.pone.0037521

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Alsiö, Å., Rembeck, K., Askarieh, G., Christensen, P. B., Färkkilä, M., Langeland, N., Buhl, M. R., Pedersen, C., Mørch, K., Haagmans, B. L., Nasic, S., Westin, J., Hellstrand, K., Norkrans, G., & Lagging, M. (2012). Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLOS ONE, 7(5), e37521. https://doi.org/10.1371/journal.pone.0037521

@article{6c34b02b50cf4a7bb30a731a905429ba,

title = "Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3",

abstract = "Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.",

author = "{\AA}sa Alsi{\"o} and Karolina Rembeck and Galia Askarieh and Christensen, \{Peer Brehm\} and Martti F{\"a}rkkil{\"a} and Nina Langeland and Buhl, \{Mads Rauning\} and Court Pedersen and Kristine M{\o}rch and Haagmans, \{Bart L\} and Salmir Nasic and Johan Westin and Kristoffer Hellstrand and Gunnar Norkrans and Martin Lagging",

year = "2012",

doi = "10.1371/journal.pone.0037521",

language = "English",

volume = "7",

pages = "e37521",

journal = "PLOS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "5",

}

Alsiö, Å, Rembeck, K, Askarieh, G, Christensen, PB, Färkkilä, M, Langeland, N, Buhl, MR, Pedersen, C, Mørch, K, Haagmans, BL, Nasic, S, Westin, J, Hellstrand, K, Norkrans, G & Lagging, M 2012, 'Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3', PLOS ONE, bind 7, nr. 5, s. e37521. https://doi.org/10.1371/journal.pone.0037521

TY - JOUR

T1 - Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3

AU - Alsiö, Åsa

AU - Rembeck, Karolina

AU - Askarieh, Galia

AU - Christensen, Peer Brehm

AU - Färkkilä, Martti

AU - Langeland, Nina

AU - Buhl, Mads Rauning

AU - Pedersen, Court

AU - Mørch, Kristine

AU - Haagmans, Bart L

AU - Nasic, Salmir

AU - Westin, Johan

AU - Hellstrand, Kristoffer

AU - Norkrans, Gunnar

AU - Lagging, Martin

PY - 2012

Y1 - 2012

N2 - Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.

AB - Having a body mass index above or equal to 30 kg/m(2) in conjunction with chronic hepatitis C virus infection is associated with non-responsiveness to treatment with interferon and ribavirin, but details regarding the mechanisms whereby obesity reduces the efficacy of therapy remain unclear.

U2 - 10.1371/journal.pone.0037521

DO - 10.1371/journal.pone.0037521

M3 - Journal article

C2 - 22655053

SN - 1932-6203

VL - 7

SP - e37521

JO - PLOS ONE

JF - PLOS ONE

IS - 5

ER -

Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3

Abstract

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater